Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $45,472 | $45,909 | $42,539 | $43,663 |
| - Cash | $2,686 | $3,273 | $3,141 | $3,045 |
| + Debt | $700 | $703 | $699 | $700 |
| Enterprise Value | $43,487 | $43,339 | $40,097 | $41,318 |
| Revenue | $1,553 | $1,532 | $1,413 | $1,386 |
| % Growth | 1.4% | 8.5% | 1.9% | – |
| Gross Profit | $1,210 | $1,190 | $1,111 | $1,094 |
| % Margin | 77.9% | 77.6% | 78.7% | 78.9% |
| EBITDA | $388 | $400 | $471 | $484 |
| % Margin | 25% | 26.1% | 33.3% | 34.9% |
| Net Income | $291 | $330 | $358 | $386 |
| % Margin | 18.7% | 21.5% | 25.3% | 27.8% |
| EPS Diluted | 0.5 | 0.56 | 0.61 | 0.65 |
| % Growth | -10.7% | -8.2% | -6.2% | – |
| Operating Cash Flow | $574 | $290 | $280 | -$128 |
| Capital Expenditures | -$58 | -$49 | -$56 | -$50 |
| Free Cash Flow | $516 | $241 | $224 | -$177 |